We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.55% | 3.275 | 3.25 | 3.30 | 3.275 | 3.225 | 3.23 | 1,718,988 | 14:30:04 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.9M | -2.6M | -0.0437 | -0.75 | 1.94M |
Date | Subject | Author | Discuss |
---|---|---|---|
17/1/2024 11:36 | Mmm ... lowest ASK on show is now up at 5.5p. The available stock is only very small. f | fillipe | |
17/1/2024 11:15 | Thanks GTC, I'll have a look | cyberbub | |
17/1/2024 11:13 | These last couple of broker notes give a good explanation of the technology which is world first. Definitely some challenges though and next trading update will be critical in determining need to raise funds again. hxxps://wp-allenby-2 hxxps://wp-allenby-2 | gtc1508 | |
17/1/2024 11:02 | What's the investment case here? Tiny market cap of £3m, losing money, possibly running low on cash, no particular IP or moat? Just looking for a home for some money, the chart looks interesting but the financials seem poor, from my quick initial look anyway. | cyberbub | |
17/1/2024 10:33 | The video I deleted is referenced in that presentation below and on their website | gtc1508 | |
17/1/2024 10:01 | No it was just a guess at why he deleted the post. | luckyabbeygale | |
17/1/2024 09:40 | CEO PRESENTATION hxxps://youtu.be/IAv | gtc1508 | |
15/1/2024 13:57 | I posted a video from there website, the link to which was circulating on twitter. Someone messaged me and said they had been asked to remove it so I also did this. | gtc1508 | |
15/1/2024 13:49 | Soo lucky have you added since reading his post? | billthebank | |
15/1/2024 13:28 | and another 200K at 12.26. I feel this rise may end up going a lot higher than the last big rise we had. | luckyabbeygale | |
15/1/2024 13:23 | I have just dicovered a very big buy of 173K at 12.15. When other people see this the buying is going to go ballistic. | luckyabbeygale | |
15/1/2024 12:21 | Looks like gtc1508 posted inside information and then deleted it. | luckyabbeygale | |
15/1/2024 12:17 | looking great!, a bit leaky i wonder? | lawson27 | |
15/1/2024 12:01 | This stock has multi bagger potential in the short term, I am surprised it dropped back so quickly after the NCI announcement | cbeadle | |
15/1/2024 11:43 | Lowest ASK on show is now 5.5p, which is being paid. f | fillipe | |
14/1/2024 18:48 | Those sellers on Thursday was like idiots taking 5p a share. Since then they have all been bought back and more. | luckyabbeygale | |
14/1/2024 17:15 | Sounded very good with results within the next 6/12 | mcbull | |
14/1/2024 16:54 | Who's this | leeawill20 | |
11/1/2024 13:29 | Looking good ?? | bigjock36 | |
11/1/2024 11:32 | Wakey Wakey | bigjock36 | |
11/1/2024 11:27 | Oh hello, someones kicking the nest, cmon FAB | lawson27 | |
10/1/2024 21:07 | He is a real life Jack ass | bigjock36 | |
10/1/2024 18:13 | Yea, question is does management really have the expertise and clout to sell the brand to big investors-not penny punters. Should be an easy sell in reality-even getting the NCI in the US to show a remote interest in their antibody library is some feat one typically underappreciated by gormless UK II analysts who don't know their ars..from their elbows, and confirms the science side of things is worthwhile. Persuading IIs that a single antibody with prospects (look at GSKs deal for early phase 2 respiratory AB they paid a billion + for the right to develop-ex China-which hasn't even been approved for clinical use yet to give one an idea of the scale and potential here. I'm afraid mgmt don't seem up to it, especially if they have to resort to Proactive to sell the story for funds. | cumnor |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions